8-K: Marinus Pharmaceuticals Defends Patent Portfolio Amidst Challenge from Ovid Therapeutics

Marinus Pharmaceuticals is actively defending its patent for ganaxolone use in treating status epilepticus following a challenge by Ovid Therapeutics, while also pursuing a post-grant review of an Ovid patent.

Summary

• Marinus Pharmaceuticals is facing an Inter Partes Review (IPR) challenge from Ovid Therapeutics regarding a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
• Marinus has invested over $100 million in ganaxolone development programs over the past two decades.
• The company believes the Ovid challenge is without merit and is committed to defending its patent portfolio.
• Marinus was granted two method of use patents for intravenous ganaxolone in the treatment of SE between 2021 and 2023.
• These patents cover the clinical dosing regimen for SE patients, including those with RSE and super refractory status epilepticus.
• Marinus initiated a post-grant review (PGR) in March 2023 challenging an Ovid patent for ganaxolone in SE.
• Ovid abandoned 23 of 31 claims in its patent in response to Marinus's PGR request.
• The Patent Office instituted the PGR on the remaining claims, and a final decision is expected by the middle of 2024.
• The PTAB stated it was more likely than not that Marinus would be able to invalidate the remaining eight claims of the Ovid 817 Patent.

Sentiment

Score: 6

Explanation: The document conveys a mix of positive and negative elements. While Marinus is actively defending its patents and has achieved some success in the post-grant review, the ongoing legal challenges introduce uncertainty and risk. The company's commitment to its mission and the potential for ganaxolone are positive, but the legal battle and associated risks temper the overall sentiment.

Positives

• Marinus has a strong patent portfolio supported by robust clinical data.
• The company has successfully obtained two method of use patents for intravenous ganaxolone in the treatment of SE.
• Marinus's post-grant review (PGR) led to Ovid abandoning a significant portion of their patent claims.
• The PTAB indicated that Marinus is likely to invalidate the remaining claims of the Ovid patent.
• Marinus has a long-standing commitment to developing innovative therapies for patients with rare genetic epilepsies and refractory seizure disorders.

Negatives

• Marinus is facing an Inter Partes Review (IPR) challenge from Ovid Therapeutics, which could potentially impact their patent rights.
• The ongoing legal challenges could be a distraction to the company's core operations.
• The outcome of the post-grant review is not yet certain, and there is a risk that Marinus may not be successful in invalidating the remaining claims of the Ovid patent.

Risks

• The company's ability to prevail in the IPR and PGR is uncertain.
• There are risks associated with unexpected market acceptance, payor coverage, or future prescriptions and revenue generated by ZTALMY.
• Unexpected actions by the FDA or other regulatory agencies could impact the company's products.
• Competitive conditions and unexpected adverse events or patient outcomes from being treated with ZTALMY could pose risks.
• There are uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• The company's ability to comply with the FDA's requirement for additional post-marketing studies in the required time frames is a risk.
• There is a risk that clinical trial results may not support regulatory approval or further development.
• Actions or advice of the FDA or EMA may affect the design, initiation, timing, continuation and/or progress of clinical trials.
• The company's ability to obtain, maintain, protect and defend intellectual property for its product candidates is a risk.
• The potential negative impact of third-party patents on the company's ability to commercialize ganaxolone is a risk.
• Delays, interruptions, or failures in the manufacture and supply of the company's product candidate could occur.
• The company's ability to obtain additional funding to support its clinical development and commercial programs is a risk.
• The potential for the company's ex-US partners to breach their obligations or terminate their agreements is a risk.
• The risk that drug product quality requirements may not support continued clinical investigation is a risk.
• The availability or potential availability of alternative products or treatments could affect the commercial potential of the company's product candidate.

Future Outlook

The company is focused on defending its patent portfolio and bringing ganaxolone to patients in need. The final decision on the post-grant review is expected by the middle of 2024.

Management Comments

• Dr. Scott Braunstein, Chairman and CEO of Marinus, stated that the company has invested more than $100 million into ganaxolone development programs in SE.
• Dr. Scott Braunstein believes the Ovid challenge is without merit and is an unfortunate distraction.
• Marinus will vigorously defend its patents which support its mission of delivering innovative new treatment options to patients with significant unmet needs.

Industry Context

This announcement highlights the competitive landscape in the pharmaceutical industry, particularly in the development of treatments for seizure disorders. Patent challenges and post-grant reviews are common occurrences as companies seek to protect their intellectual property and market exclusivity. The outcome of these legal proceedings could have significant implications for the commercialization of ganaxolone.

Comparison to Industry Standards

• Patent disputes are a common occurrence in the pharmaceutical industry, with companies like AbbVie and Amgen frequently involved in litigation to protect their intellectual property.
• The investment of over $100 million in ganaxolone development is significant, but not uncommon for companies developing novel therapeutics, with companies like Biogen and Vertex investing similar amounts in their respective programs.
• The post-grant review process is a standard procedure for challenging patents, and the PTAB's decision to institute the review and its preliminary assessment of Marinus's case are consistent with industry norms.
• The abandonment of 23 claims by Ovid is a significant concession and suggests that Marinus's challenge has merit, similar to cases where companies have withdrawn patent claims in response to challenges from competitors.

Legal Proceedings

• Marinus is facing an Inter Partes Review (IPR) challenge from Ovid Therapeutics regarding a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
• Marinus initiated a post-grant review (PGR) challenging an Ovid patent for ganaxolone in SE.

Stakeholder Impact

• Shareholders may be concerned about the potential impact of the patent challenge on the company's future revenue and profitability.
• Employees may be affected by the ongoing legal proceedings and the potential impact on the company's operations.
• Patients and families affected by seizure disorders may be impacted by the outcome of the patent dispute and the availability of ganaxolone as a treatment option.
• Creditors may be concerned about the company's ability to repay its debts if the patent challenge is unsuccessful.

Next Steps

• Marinus will continue to defend its patent portfolio against the IPR challenge from Ovid Therapeutics.
• The company will continue to pursue the post-grant review of Ovid's patent.
• A final decision on the post-grant review is expected by the middle of 2024.

Key Dates

Keywords

ganaxolone, status epilepticus, refractory status epilepticus, patent, intellectual property, Inter Partes Review, post-grant review, Ovid Therapeutics, Marinus Pharmaceuticals, seizure disorders